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LONGITUDINAL CHARACTERIZATION OF DEPRESSION AND MOOD STATES 
BEGINNING IN PRIMARY HIV INFECTION. Jessica A. Gold, Marie Grill, Julia 
Peterson, Christopher Pilcher, Evelyn Lee, Frederick M. Hecht, Dietmar Fuchs, 
Constantin T. Yiannoutsos, Richard W. Price, Kevin Robertson, and Serena Spudich. 
Department of Neurology, Yale University, School of Medicine, New Haven, CT.   
 
Though depression is known to frequently afflict those with chronic HIV, mood during 
the early course of HIV is not well characterized. In a prospective study we assessed 
mood during primary HIV infection (PHI, <1 year duration), its association with 
neuropsychological performance and markers of neurological disease, and its longitudinal 
course including effects of highly active antiretroviral therapy (HAART). The Beck 
Depression Inventory (BDI) and Profile of Mood States (POMS) subscales were 
longitudinally administered prior to and after HAART in PHI subjects. This evaluation of 
mood was done concurrently with blood, cerebrospinal fluid (CSF) and 
neuropsychological (total z and global deficit score, GDS) evaluation at each visit. 
Analysis employed Spearman’s rho, logistic regression, and linear mixed models. 47.7% 
of the 65 men recruited at a median 3.5 months HIV duration met BDI criteria for clinical 
depression at baseline, classified as ‘mild’ (n=11), ‘moderate’ (n=11), or ‘severe’ (n=9). 
Drug, alcohol, and depression history did not associate with BDI score. Proportional 
somatic-performance scores were worse than cognitive-affective scores (p=. 0045). Vigor 
subscore of POMS was reduced compared to norms and correlated with total z (r=0.33, 
p=0.013) and GDS (r=-0.32, p=0.016).  BDI and POMS correlated with one another 
(r=0.85, p< .0001), but not with CSF or plasma HIV RNA, white blood cell (WBC) 
count, albumin ratio or neopterin. Improvement was not observed in BDI and POMS over 
330 total follow-up visits, even after initiation of HAART. Depression was prevalent 
  
 
 
 
during PHI in our subjects, associated with abnormal somatic-performance and vigor 
scores. Neither neuropsychological performance nor disease biomarkers correlated with 
depressed mood. Mood indices did not improve over time in the presence of HAART.  
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1 
INTRODUCTION 
HIV/AIDS: The Problem in the U.S. 
 
“When I tested positive it was very clear to me that I would die”(1). 
Knowing that this quotation comes from an interview with an HIV-infected person within 
2 months of diagnosis, one might expect this person to have been diagnosed in the early 
era of HIV infection, the 1980s. This assumption occurs because over the past few 
decades, the picture of HIV/AIDS in the United States has changed dramatically. 
Research advances have helped to: prevent vertical transmission (mother to child), 
improve screening blood and blood products for the virus, and develop successful 
treatment regimens (2). With suppressed viral replication due to highly active 
antiretroviral therapy (HAART), patients are also less infective to their sexual partners 
(3). As a result, there has been a significant decline in the HIV infection rate in the 
United States from 130,000 new cases a year in 1984 to 60,000 in 1991 (2) (See Figure 
1) (4). 
Beyond the decrease in new cases, HIV is also no longer unavoidably fatal. In 
fact, the loss of life years due to HIV (approximately 7) is equated to that due to a 
lifetime of cigarette smoking, or close to the levels of the uninfected population with 
chronic disease (5,6). Additionally, AIDS-related illnesses, such as pneumocystis 
pneumonia, are no longer the primary causes of death in AIDS patients, and instead, new 
complications of chronic disease have taken their place (7). In just a few decades, HIV 
has gone from a fear-inducing disease that was a death sentence, to a chronic illness that 
is manageable with medication (8). In response, much of our public health focus and 
  
 
 
 
2 
attention has turned to Sub-Saharan Africa where 2/3 of the cases of AIDS now reside 
(2).  
 
 
Figure 1. AIDS in the US from 1981 to 2008: Diagnoses, Deaths, and Living with 
HIV Infection or AIDS in Persons 13 or Older. Following the introduction of HAART 
around 1995, there has been a stable incidence of approximately 50,000 new cases/year. 
Source: CDC. Morbidity and Mortality Weekly Report. HIV Survelliance-US, 1981-2008. 
2011; 60(21):689-693. 
 
However, the initial expectation that the patient interviewed above was 
interviewed in the 1980s, is wrong. In fact, this study was conducted within the past year. 
While there have been vast scientific advances, a decrease in incidence and mortality, and 
a change to the cultural concept of HIV as a disease, fear about HIV persists. Why is it, 
then, that this patient, and 23% of the rest of the interviewed sample, still feel that HIV is 
a fatal diagnosis (1) ? 
 
  
 
 
 
3 
Perhaps this is because that while the incidence of HIV has remained stable at 
about 50,000 new cases of HIV a year in the US (9) (Figure 1), certain high risk groups, 
such as the 86% men who have sex with men (MSM) interviewed for the study (1), are 
disproportionately affected (See Figure 2)(10). In some urban areas, the HIV prevalence 
among MSM is as high as 30%, a number significantly greater than the general 
population prevalence of both Kenya (7.8%) and South Africa (16.9%)(2). Clearly, the 
burden of HIV infection today is not solely an international problem. 
 
 
Figure 2: Rates of New HIV Infections in the US in 2010, by High-Risk Subgroup. 
HIV in the US disproportionally affects African Americans and Hispanics as well as 
MSM. Source: CDC.HIV in the US: At a Glance.http://www.cdc.gov/hiv/statistics/basics/ 
ataglance.html 
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Beyond greater concentrations of disease in disadvantaged populations and a 
greater concentration of HIV in urban areas, with 50% of persons living with HIV in the 
US located in only 12 cities (9) (see Figure 3), new cases are also found much more 
commonly in these groups. In fact, even though MSM represent about 4% of the male 
population in the US, they account for 63% of all new infections (10). This percentage, 
unlike the overall incidence of HIV in the US, has not remained stable. Instead, it has 
increased 12% in just two years (from 2008 to 2010) (10). In addition to MSM, HIV in 
the US also disproportionally affects African Americans and Hispanics. While African 
Americans represent only 12% of the US population, they account for more than 44% of 
the new HIV infections (10,11). Hispanic males are also disproportionally affected, 
infected at 2.9 times the rate of new infections in white males (10). Other risk factors 
such as intravenous drug use (IVDU), excessive alcohol and cocaine intake, and risky 
sexual behaviors continue to pose a threat for HIV acquisition (2), and as a result, HIV is 
found more often in populations with more risk. In these social and sexual networks, HIV 
remains highly concerning and even subjectively instills a sense of impending doom 
around the diagnosis. 
Additionally troubling, despite widespread screening methods, is the fact that 1 in 
6 persons living with the disease are unaware of their status (11). This means that despite 
effective treatment, patients will present late in the course of their infection, decreasing 
their life expectancy and increasing the probability of transmission to others (6). Stigma 
remains a serious impediment to screening and ultimately treatment (1). Given these 
discrepancies, it is clear that combating HIV/AIDS in the US is not finished and remains 
a significant public health issue, especially in populations that are “disenfranchised and 
  
 
 
 
5 
socially marginalized” (2). It is thus understandable that the patient interviewed felt HIV 
was still a death sentence in 2013. 
 
 
Figure 3: A Map of the Diagnoses of HIV Infection in 2010.  
In 2010, the estimated number of new diagnoses of HIV infection in the US was 48,298. 
This rate varies widely across the US and US dependent areas: from zero in American 
Samoa and the Northern Mariana Islands to 6,417 in California. Source: CDC. HIV 
Surveillance Report , 2011; vol. 23. http://www.cdc.gov/hiv/topics/surveillance/ 
resources/reports/. Published February 2013.  
 
HIV/AIDS: The Disease and Its Treatment 
 
Acknowledging the problem of HIV in the US, it is also important to understand the 
basics of the virus’s time course and treatment. HIV is a retrovirus (more specifically a 
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lentivirus) that can be transmitted from sexual contact, IVDU, contact with infected blood 
products, or from mother to child (12). It infects cells in the immune system, such as 
helper T cells, macrophages, and dendritic cells, following the interaction of a viral 
surface protein known as the glycoprotein 120 (gp120) and CD (or the cluster of 
differentiation) receptor number 4 (CD4), which is expressed on T-lymphocytes, 
monocytes, macrophages, and dendritic cells (13). Once the virus enters the cell and HIV 
RNA is reverse transcribed to DNA, the virus can either lie dormant in the latent phase of 
infection or lead to a decline in CD4 (through mechanisms such as apoptosis and killing 
of infected cells (14)). This decline will ultimately cause a decrease in cell-mediated 
immunity, or, more specifically, will decrease the body’s ability to fight infection (12). 
The clinical presentation of HIV begins with primary HIV infection (PHI), in 
which a patient develops a “flu-like” syndrome approximately 14 days following 
transmission (see Figure 4). Clinically, patients may experience a fever, fatigue, sore 
throat, a rash, and even a headache, while biologically there is an increase in HIV RNA 
and a decrease in CD4 count (15,16). During this period, health care providers often miss 
the diagnosis of HIV, and, in one study only 25% of patients were correctly diagnosed by 
providers during an appointment in this time period (15). This early period, however, is a 
critical time for the course of infection as HIV tissue reservoirs and CD4 memory 
phenotype T-cells are produced, and viral and immune activation set points are 
determined (17). Virus can also be found in immunologically privileged areas in the 
CNS, such as the brain and spinal fluid, during this time (18,19) 
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Figure 4: Typical Course of HIV Infection in an Untreated Individual. In this figure, 
red represents CD4 count and blue the HIV RNA copies/ml plasma. Notice how primary 
infection is associated with a rise in the plasma HIV RNA within the first three weeks of 
viral infection. Patients then develop anti-HIV cytotoxic T lymphocytes causing the CD4 
count to decline. After a brief recovery of immune cells, infected individuals enter 
clinical latency, in which the CD4 count declines slowly over time. If HAART is not 
initiated, the CD4 count falls to a critically low level, the patient is susceptible to 
opportunistic infections, and will develop AIDS. Re-Printed with permission courtesy of 
A.S. Fauci, National Institute of Allergy and Infectious Diseases, NIH 
	  
  
Following primary infection, the massive peak in the plasma viral load subsides as do the 
clinical symptoms and the patient reaches the clinically quiescent phase. In this phase, 
viral particles are produced at a high rate, and CD4 cells are destroyed and replenished 
daily (20, 21). Over time, a patient’s CD4 cell count will decrease substantially and 
individuals will become susceptible to severe infections and the development of AIDS. 
This time span ranges from less than one year to more than 20 (21).   
In terms of treatment, the first antiretroviral drug was introduced in 1987, 
zidovudine, and for many years this drug, and others in the nucleoside reverse 
transcriptase inhibitors class were used as mono, and the only available, treatment. 
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Approximately 10 years later, protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors were introduced. The discovery of these additional classes of 
drugs subsequently led to combination therapy, or the use of three drugs, from 2 different 
classes. This treatment modification, now known as HAART, extended survival 
dramatically (12). Yet, because of the blood-brain-barrier (BBB), HIV in the brain can be 
protected from the full effect of antiretroviral agents, especially those drugs that are large 
or hydrophilic. To date, studies have found choosing drugs with higher CNS-penetration-
effectiveness scores (CPE) can lead to more effective viral suppression (22,23), however, 
this is not yet recommended practice. 
Over the years, treatment guidelines for clinicians have changed with the most 
current recommendations suggesting that HAART be offered to all patients regardless of 
their CD4 count (24). However, a patient’s willingness to take the treatment consistently, 
challenged, in part, because of significant drug side effect profiles including 
lipodystrophy, lactic acidosis, and insulin resistance, is a significant factor in treatment 
success (12). Drug resistance can occur in the setting of poor adherence secondary to the 
high replication rate of HIV infection and the high error rate of reverse transcriptase (12). 
Clinically, patients will observe a decreased susceptibility to a specific drug, and 
ultimately, may fail to have a beneficial response to their HIV treatment regimen.  
At first thought to potentially cure HIV, it is now recognized that HAART is not a 
cure, but is instead a life-extender. This is because HIV also infects long living cells like 
microglia and has latency in memory CD4 cells (25), and therefore, never entirely goes 
away. Though the CD4 count in treated patients will often increase (improve) over time 
suggesting a greater ability for the patient to fight infection, immune dysfunction, 
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inflammation, and coagulation disorders will persist. HIV-infected patients are then at 
high risk for cardiovascular, kidney, and liver disease, as well as malignancy (7). 
Additionally, it is believed that HIV can affect the central nervous system (CNS), in part, 
because HAART is systemically suppressive, allowing infection, inflammation, and brain 
injury to remain active and progressive over time (17).  
HIV/AIDS in the Central Nervous System: Mechanism and Effects 
 
Though reasons that HIV is able to impact the nervous system during HAART remain 
hypothetical, what is known is that HIV entry is associated with immune activation and 
inflammation in the CNS. The virus is able to traverse the BBB in infected monocytes 
and lymphocytes, (26) (See Figure 5, a), a hidden mechanism often referred to as the 
“Trojan horse.” Once inside, the monocytes change into perivascular macrophages and 
eventually release viral proteins that are known to exert toxic effects upon neurons or 
astrocytes (17). Microglia also become infected (27)(See Figure 5,b) and in some cases 
form large multinucleated giant cells with infected macrophages that  serve as a virus 
production reservoir (see Figure 5,c). Infected cells further promote astrocytosis with the 
dysregulation of cytokine production. These cytokines inappropriately act to recruit 
activated T-cells from the periphery and activate uninfected cells. Ultimately, this will 
lead to a further increase in the permeability of the BBB and additional leakage of cells 
and inflammation products into the CNS (12,27). 
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Figure 5:  HIV Invasion of the CNS. HIV uses a Trojan horse mechanism to enter the 
BBB in infected monocytes. Inside, these become perivascular macrophages and 
microglia. Infected cells will induce astrocytosis and further increase permeability of the 
BBB. Reprinted by permission from Macmillan Publishers Ltd:[Nature](González-
Scarano, F.& Martín-García, J. (2005). The neuropathogenesis of AIDS. Nature Reviews 
Immunology, 5(1), 69-81), Copyright (2005), as well as Drs. González-Scarano and Julio 
Martín-García 
 
The CNS is infected very early in the course of HIV infection, during primary 
HIV (15).  Even in the early months of infection, HIV is associated with inflammatory T-
cells in the brain, an increase in cytokines, and the activation of microglia (17). The CNS 
reservoir for infection and inflammation is also established during this time period (17).  
Following the clinical picture of an acute retroviral syndrome, some infected individuals 
will develop neurological complaints, such as meningitis or encephalitis. As these 
symptoms are often self-limited, they are believed to be autoimmune in etiology (17).  
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Yet, the persistence of HIV associated cognitive impairment, despite the initiation and 
success of HAART, suggests that this early period, before even the HIV diagnosis is 
made, might cause irreversible damage to the CNS in infected persons (17).  
In the days before HAART, one of the more common manifestations of HIV 
infection, occurring in up to 70% of infected individuals, was neurological disorders (28). 
More often associated with advanced illness and not primary infection (29,30), these 
disorders included opportunistic infections such as toxoplasmosis, progressive multifocal 
leucoencephalopathy (PML) and primary CNS lymphoma, as well as the previously-
named AIDS dementia complex (31). In the latter, now called HIV-associated dementia, 
patients presented with cognitive, motor and behavioral symptoms, but would often only 
receive this diagnosis when all other causes were ruled out (32). At first these patients 
would have difficulty concentrating and have mental slowing, and over time, developed 
motor symptoms including slowing of rapid movements and hyperreflexia (33).  
Additionally, one large study found that in 1/3 of patients behavior change including 
apathy and social withdrawal was prominent  (32).  
With the discovery of HAART, HIV-Associated Neurocognitive Disorder 
(HAND) no longer manifests as HIV-associated dementia, but is instead presents as more 
subtle disturbances in psychomotor speed, processing speed, executive function, and/or 
memory (17). The disorders may be milder than in the pre-ART era, but the presence of 
cognitive impairment is still associated with an increased overall disease morbidity, 
thought due in part to low adherence to medication regimens in these patients (34). 
Additionally, HAND has been shown to correlate with the CD4 nadir (34), suggesting 
that  patients with the largest immunologic ‘hit’ from HIV are most prone to develop 
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neurocognitive dysfunction. Ultimately, even in the presence of successful treatment with 
HAART, patients continue to be affected by HAND today. 
HIV and Depression 
 
Patients with chronic medical illnesses have, in general, a two-to-threefold higher rate of 
major depression compared with age and gender matched patients who do not have a 
chronic illness (35). This is particularly significant as depressed patients appear to die 5 
to 10 years earlier than patients without psychiatric disorders (35). In addition, the 
patients who are also depressed more often report higher numbers of physical symptoms 
such as fatigue (even when controlling for severity of the baseline medical disorder) 
(35,36), have higher levels of subjective pain assessment, and contribute to a two-fold 
higher cost to the medical system (36). This cost is often secondary to increased 
functional impairment, twice as many health care visits, and a three times lower 
adherence to self-care regimens in this population (35). Yet, improving depression 
decreases somatic symptom complaints in these patients (36) and improves health care 
outcomes. That being said, given that HIV in the post-ART era has been transformed to a 
chronic illness (7), depression in this population can be presumed to be costly, both to the 
patient and to the health care system. 
Reports of the prevalence of depression over the course of HIV infection vary 
widely (37-39), however, one meta-analysis found that the diagnosis of Major Depressive 
Disorder is nearly twice as likely in HIV-infected persons as compared to those without 
HIV (39). Major Depressive Disorder can be defined using the DSM IV classification, in 
which a patient must have depressed mood and/or loss of interest or pleasure in life 
activities plus 5 of the following symptoms for at least 2 weeks: depressed mood, loss of 
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interest, significant unintentional weight gain, insomnia, psychomotor retardation, fatigue 
or less of energy, feelings of worthlessness or guilt, diminished concentration, and 
suicidality (40). One reason for such a strong association between depression and HIV 
may be overlap in symptoms between depression and HIV infection itself, as appetite 
disturbance, fatigue, and concentration problems are all associated with HIV as well as 
depression (38,41-43). In fact, frequency of HIV symptoms and symptom distress were 
found to increase with level of depression or anxiety (44). Yet, studies suggest that 
depression is symptomatically different between HIV-infected and HIV-uninfected 
persons. The most common symptoms reported among HIV-infected subjects is sleep and 
appetite disturbances, while HIV-uninfected subjects more commonly endorse decreased 
energy and libido (38). Additionally, depressive symptoms can be caused by both the 
opportunistic infections associated with HIV, which alter mood and cognition, and the 
side effects of antiretroviral therapy, which can cause agitation, depressed mood, 
decreased cognition and insomnia (38).  One study found that more side effects from 
treatment predicted depression (45). Complicating matters further, variables such as 
employment status, gender, history of attempted suicide, sexual orientation, history of 
depression, illicit drug use, drug dependence, heavy alcohol use (more than 7 drinks a 
week for a woman and more than 14 for a man), and social class are all independently 
associated with increased risks of depression and can subsequently alter the prevalence of 
and susceptibility to of depression in this population (37,38,46-48). Stigma in this 
population, which leads to isolation and lack of social support, is also correlated 
significantly with higher levels of depression (45,48,49). Perhaps because physicians 
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attribute behavioral change to the disease itself, depression in HIV infected persons often 
is underdiagnosed (38).  
Though it is known that depression is common in HIV infection, it is not clear 
when depression arises during the course of infection or how this relates to other events 
of HIV pathogenesis. In general, cross-sectional rates of Major Depressive Disorder are 
similar in asymptomatic disease and in more advanced HIV disease (39). Unlike in the 
general population, depression rates do not seem to decline with age in HIV infected 
populations (47). Indeed, studies have shown no increase in the rates of depression in 
later stage disease even in patients more medically ill (43,50), and have found no 
consistent association with either CD4 cell count or HIV viral load (39,51,52). For 
example, some studies have found an association between low CD4 count and 
depression, while others found no association. Depression has also not conclusively been 
found to affect performance on neuropsychological testing (37,53,54).  Despite an 
unclear association between depression and these medical and neurological aspects of 
HIV infection, one study did find that depressive symptoms were associated with an 
increased mortality in HIV-positive women (43,55). 
It is often debated whether, when depressed mood and HIV infection are 
identified concomitantly, depression was a premorbid condition in a person who was at 
high risk of HIV acquisition, or whether depression followed HIV infection.  There are 
theories, however, suggesting that there may be a biological basis to the depression seen 
in HIV infection. One idea is that the cytokines produced by the macrophages in the HIV 
infected CNS lead to depression (48,56). This concept is supported by the discovery of 
elevated inflammatory markers, such as cytokines, in depressed human patients, the 
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finding of high levels of depression in people with inflammatory illnesses, and the 
relation between acute inflammation in mammals and behavioral changes similar to 
depression known as “sickness behavior” (56). Another hypothesis suggests that gp120 
inhibits the dopamine transporter, increasing dopamine levels in the synapse and 
promoting HIV replication. HIV then destroys the dopaminergic basal ganglia neurons 
leading to depression (48,56). A final theory suggests that stress from illness increases 
corticotropin releasing hormone and cortisol levels, leading to depression (38,48,56). On 
the other hand, some argue that mood changes in this population could have preceded 
infection with HIV, instead of secondary to the illness itself (57). This means that those 
with a history of a mood disorder, or those populations at high risk of having a mood 
disorder (MSM and IVDU), are at an increased risk for contracting HIV (58). Whether 
behavioral, social, or reactionary, this risk for HIV infection in populations with a high 
baseline risk of depression leads to higher rates of depression overall in this population 
(43). Developing depression may then either be a result of previous depression, or HIV’s 
affects on the CNS (59). 
While the timing of the relationship between initiation of depression and HIV 
remains unproven, what is evident is that depression can impact HIV disease progression 
and treatment outcomes. Having depression is associated with a faster progression to 
AIDS and increased risk of mortality associated with HIV (59). While this may be related 
to an association between depression and impaired immune function (53), it may also 
correlate with decreased medication adherence and incomplete virologic suppression (38, 
43, 52) among HIV infected individuals on HAART. In fact, in one meta-analysis, 
depression was consistently associated with non-adherence in all samples over time (60). 
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This effect (r-.19) was similar to the effect (r=.21) in meta-analyses of depression and 
other chronic illnesses (60). Additionally, as one study found an inverse association 
between depression and HAART, suggesting lower levels of depression in patients on 
HAART, and this association was found to increase with time on HAART, some 
postulate there is a protective effect of HAART on patients against depression (61). 
Given that non-adherence is associated with an increase risk of treatment failure and viral 
resistance, and, that there are potential mood benefits to using ART, diagnosing and 
properly treating depression in HIV infected patients becomes critical.  
In this population, study after study has suggested the benefits of antidepressant 
use. Antidepressants have been shown to be an effective treatment for HIV infected 
patients with depression (38,41,58,62); antidepressant use in one month has been 
associated with a 28% increase in the odds of HAART use in the subsequent month (63). 
Furthermore, in a different study, the odds of adhering to HIV-treatment were 83% better 
if a patient was having their depression treated (64). In terms of which antidepressant is 
safe and effective in this population, though serotonin reuptake inhibitors (SSRIs) were 
found to be as effective as tricyclics, SSRIs were often the drug of choice due to their 
much safer side effect profile (38,43). Nonetheless, as remission of depression was 
associated with lower viral load or a decrease in the amount of virus (65), treating 
depression is crucial for medication adherence, and treating HIV. 
For all of these reasons, understanding and treating depression in HIV-infected 
patients is of central importance in improving clinical outcomes. With new HIV clinical 
practice guidelines (24) recommending treating all HIV-infected patients with HAART, 
including those in very early HIV infection, early interventions to enhance adherence to 
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HAART and its effectiveness will be critical in preventing the transmission of drug 
resistance. Better understanding of the role of depression in the early stages of HIV has 
emerged as an important question in the public health approach to HIV treatment.    
This study seeks to elaborate on our understanding of HIV and depression by 
focusing on subjects with primary HIV infection (PHI), or those infected within the past 
year. As mentioned previously and clarified here, during the early weeks after exposure 
to HIV, up to 10% of individuals develop neurological signs and symptoms of disease, 
and HIV can be detected in both cerebrospinal fluid (CSF) and brain tissue (18,19). PHI 
is also associated with impaired performance on neuropsychological testing and with 
neuroinflammation as measured in CSF (66,67). Yet, to date, only one study has looked 
at and reported on the prevalence of symptoms and signs of mood disorders during the 
early stages of HIV infection (68). This study measured depression in 34 individuals with 
PHI using qualitative methods (the Mini International Neuropsychiatric Interview) and 
quantitative self-report comparisons (the Beck Depression Inventory (BDI), the State-
Trait Anxiety Inventory). The authors found that almost 40% of their subjects were 
categorized as depressed in the clinical range, though most depression was “mild”, and 
that subjects had a strong reliance on adaptive coping approaches (68).  We aimed to 
further characterize depression in PHI, by assessing mood states in subjects with PHI 
with additional measures, and correlating mood indices with measures of CNS 
inflammation and infection in the CSF and with measures of cognitive performance. In 
addition, we longitudinally assessed mood scores in this observational study, including 
visits both prior to and after initiation of HAART, to evaluate the trajectory of depression 
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in this population over time and association of mood scores with the commencement of 
HAART.  
HYPOTHESES 
Depression and otherwise altered mood states are prevalent in the first months after HIV-
1 transmission (during PHI) and will persist longitudinally despite initiation of HAART.  
Indices of altered mood states may correlate with CNS inflammation as measured in CSF, 
or with performance on neuropsychological testing.  
SPECIFIC AIMS 
1) To quantify and describe the extent of depression symptomatology and the range of 
mood states of individuals during the first six months after HIV exposure based on 
baseline scores on the validated Beck Depression Inventory (BDI) and Profile of Mood 
States (POMS) assessments obtained from a cohort of subjects with primary HIV 
infection.  
2) To investigate whether baseline levels of depression in PHI (as measured by the BDI 
and POMS) correlates with known biomarkers of HIV burden and inflammation and host 
responses in the CNS to infection.  
3) To examine whether the baseline levels of depression in PHI (as measured by the BDI 
and POMS) correlate with cognitive impairment based on neuropsychological testing. 
4) To longitudinally assess mood states in patients with HIV, from acute infection to up 
to 3 years post infection, taking into account the effects of HAART initiation in this 
cohort. 
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METHODS 
As lead investigator on this highly collaborative project, Jessica Gold was responsible for 
the key aspects of the study.  Importantly, she conceived of the study concept.  Though 
the cohort study was planned and implemented prior to her participation and relevant data 
to this project was in the process of collection, the specific analysis of mood features in 
correlation with laboratory and clinical features was an idea that she developed and 
pursued.  After planning the study design and analysis, plan, she performed all of the key 
aspects of implementing the project, including reviewing the subject data and excluding 
inappropriate subjects, cleaning the dataset, tallying the mood inventory data from 
individual forms filled out by study subjects, organizing the data into spreadsheets, and 
performing data analysis. She performed all of the baseline cross sectional analysis and 
summary statistics, and worked closely with Dr. Constantin Yiannoustsos, a professor of 
statistics, to perform the complex analysis of longitudinal data.  She also was responsible 
for creating figures and tables, as well as all of the writing that accompanied the research, 
with editing help from Dr. Serena Spudich and other collaborators. The other 
investigators were responsible for recruiting subjects, collecting or storing specimens, 
neuropsychiatric testing, conducting detailed medical histories, and performing 
laboratory assays. Collaborators also worked closely with the primary author in 
performing the complex statistics required for cofounders analysis (such as substance 
abuse) and the complex longitudinal data analysis and graphing as noted above, as well 
as assisted with normalizing the neuropsychiatric data.  
Study Design and Subjects 
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Study subjects were enrolled in an observational longitudinal neurological study of PHI 
based at the University of California, San Francisco (UCSF), the Primary Infection CNS 
Events Study (PISCES)(66). Subjects with known or suspected HIV infection within the 
past year were referred to PISCES from local HIV testing centers or from a parallel 
systemic study of PHI, the UCSF Options Study. Subjects were over the age of 18, 
identified within the first twelve months after HIV-1 transmission as defined either by 
seroconversion on standard HIV serologic testing or by a less-sensitive HIV antibody 
EIA indicating early infection as previously described for this cohort (69,70). For 
subjects reporting classic acute retroviral symptoms within the seroconversion period, 
infection was estimated as having occurred 14 days prior to onset of acute retroviral 
symptoms (71). In the absence of such symptoms, the infection date was estimated as 
occurring halfway between the last negative and first positive HIV test (72). 
Study visits occurred at baseline, 6 weeks, 6 months, and every 6 months 
thereafter indefinitely. Subjects were HAART naïve at the first visit, and some started 
HAART at variable times during the course of follow-up for reasons outside of the 
observational study. At each visit, subjects underwent a record review, a full neurological 
history and examination, a detailed battery of neuropsychological testing, depression 
screening, and lumbar puncture and phlebotomy. The Institutional Review Boards at 
UCSF and Yale approved study protocols, and informed consent was obtained from all 
subjects.   
Depression Measures 
The BDI-II (73) and POMS (74) measures were administered at each study visit. Study 
subjects completed these instruments using the standard instructions and with the help of 
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study staff that were available for questions and to make sure that subjects understood 
and properly completed the screens. 
The BDI-II consists of 21 items. Study subjects choose a phrase that is most 
associated with how they are feeling ranked on a Likert Scale. The total number of points 
for the entire instrument is then calculated to measure the total BDI score; higher scores 
indicate a more severe depression. The standard cut-offs for the BDI-II indicate that a 
score of 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate 
depression, and 29-63 is severe depression. In addition, to properly compare with the 
study by Atkinson et al, the only other study of depression in subjects with PHI, clinical 
depression was defined as a total BDI>13 (68). To calculate BDI subscale scores, items 
1-13 scores were tabulated for the cognitive/affective score, which includes items such 
as self-dislike, pessimism, and worthlessness, and the points for the remaining items (14-
21) were summed for the somatic score, which involves such symptoms as change in 
appetite, loss of interest in sex, irritability, and concentration difficulties (75). Proportions 
were calculated to compare the subscale scores to each other by dividing the raw score by 
the possible total score for each subscale.  
The POMS consists of 65-words or brief phrases on a Likert scale. Raw scores for 
the mood states of depression, tension, anger, fatigue, confusion, and vigor are then 
calculated using standard analysis methods leading to a raw score of <60 for each mood 
state. Total Mood Disturbance (TMD), is calculated by the sum of the raw scores from 
tension, depression, anger, fatigue, and confusion, with the vigor score subtracted. This 
gives a TMD in the range of -24 to 177, with a lower score representing more stable 
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mood. In our analysis, subscale and total scores were converted to z scores for 
normalization. 
Specimen Sampling, Processing and Laboratory Studies 
CSF, blood, and general medical and neurological assessments were obtained as 
previously described (76,77). Briefly, this involved CSF collection via lumbar puncture, 
wherein subjects, after specific consent for lumbar puncture procedure, were prepped and 
draped, lay in a lateral supine position, and had a small amount of 1% lidocaine 
introduced subcutaneously and then in the slightly deeper soft tissues for local anesthesia.  
After accomplishment of anesthesia, a Sprotte pencil point CSF collection needle with 
introducer was inserted into the anesthetized space and approximately 20 cc of CSF was 
collected.  After the procedure, subjects rested and underwent phlebotomy for blood 
collection for paired blood lab analysis.  From CSF, total white blood cell (WBC) count, 
protein, and albumin were measured in the clinical laboratory on fresh samples.  From 
blood, background labs including complete blood count and chemistries, as well as blood 
albumin and blood CD4+ and CD8+ T lymphocyte counts by flow cytometry were 
measured on fresh samples. The remainder of the samples were centrifuged and cell-free 
CSF and blood plasma were also aliquoted and stored within 6 hours of collection in -70 
deg C freezers monitored for temperature on a daily basis using NIST-certified 
thermometers.  
 
Immune Biomarker Methods 
CSF and plasma concentrations of the macrophage activation marker neopterin 
(BRAHMS Aktiengesellschaft, Hennigsdorf, Germany) was measured in previously 
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frozen samples in the laboratory of Dr. Fuchs by commercial immunoassay.  Neopterin is 
a sensitive measure for cellular immunoactivation (78) and chemokines mediate HIV-
infected leukocytes through the BBB. MCP-1 recruits monocytes and macrophages, 
typically at low levels in asymptomatic HIV-infected individuals (79 80).   
CSF chemokines interferon-inducible protein-1 (IP-10) and monocyte-chemoattractant 
protein-1 (MCP-1, R&D Systems, Minneapolis, MN) were also measured in previously 
frozen samples locally at UCSF by commercial immunoassays. IP-10 is produced by T-
cells, macrophages, astrocytes, and endothelial cells, and attracts immune cells, primarily 
T lymphocytes, from the periphery across the blood brain barrier (81). Levels of IP-10 
often correlate with CSF mononuclear and HIV RNA levels (82).  MCP-1 is also 
produced by immune cells including resident microglial cells and macrophages within the 
CNS, primarily attracts monocytes across the blood brain barrier, and in advanced HIV is 
highly correlated with presence of HIV dementia. 
 
Virological Methods 
HIV RNA levels were measured in previously frozen cell-free CSF and plasma using the 
ultrasensitive (50 copies/mL lower limit of detection) Amplicor HIV Monitor (version 
1.5; Roche Molecular Diagnostic Systems, Branchburg, NJ), or the Abbott RealTime 
HIV-1 (Abbot Laboratories, Abbot Park, IL, USA) assays. Paired blood and CSF 
measurements were made using the same assay, typically in the same PCR run.   
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Neuropsychological Testing 
Neuropsychological testing performed by a trained psychometrist employed an 11 test 
battery encompassing five neurological/cognitive domains, including motor (timed gait, 
grooved pegboard, finger tapping, non-dominant hand); executive function (trailmaking 
B & Controlled Oral Word Association Test); processing speed (WAIS-R digit symbol, 
trailmaking A); memory (RAVLT delay, figure delay); and learning (average of RAVLT 
trials 1-5, figure memory learning). All measures except timed gait were normed 
according to age, education, gender, and ethnicity. Measures were summarized as a brief 
NPZ4 (average of performance on 4 tests: timed gait, grooved pegboard, finger tap and 
digit symbol), total Z (average of performance on all 11 tests), and global deficit score 
(uses a standardized conversion table to convert demographically corrected Z scores on 
individual NP measures to deficit scores ranging from 0 (no impairment) to 5 (severe 
impairment)). 
 
Statistical Analysis 
Baseline descriptive statistics were performed using GraphPad Prism (version 5.0, 
GraphPad Software, San Diego, USA). Spearman’s non-parametric correlation was used 
for correlation between measured parameters at baseline.  Cross-sectional baseline group 
differences were detected through the Mann-Whitney rank sum test and the Kruskal-
Wallis test with post-hoc testing corrected for multiple comparisons. Longitudinal 
analysis was performed using SAS (version 9.0, SAS Institute, Inc., Cary, NC) and 
employed a mixed-effects model with covariates of weeks of infection and time-by-ART 
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interaction in subjects starting HAART to analyze longitudinal BDI and POMS total 
scores. 
RESULTS 
Baseline Study Subject Characteristics  
65 subjects (all men) with a median age of 36 qualified to participate in this study. They 
also had a median of approximately 3.5 months (103.5 days) of infection at baseline, and 
median CD4 count of 558. One subject included in this study who met BDI criteria for 
severe depression committed suicide after the first visit. Other baseline features of the 65 
subjects (including prior treatment for depression and substance use) are presented in 
Table 1.  
 
Table 1: Baseline Characteristics of Study Participants. N = 65 subjects, 100% male, 
all but 3 self-identified as MSM  
 
 
	  
Age	  (years)	  
Days	  post	  HIV	  
exposure	  
Years	  of	  
education	  
Plasma	  HIV	  
RNA	  (log10	  
copies/ml)	  
CD4	  count	  
(cells/	  mm3)	  
CSF	  HIV	  
RNA	  (log10	  
copies/ml)	  
CSF	  WBC	  
(cells/ul)	  
Median/	  
Absolute	  
Total	  
36	   103.5	   16	   4.5	   558	   2.6	   6	  
Interquartile	  
Range	  
(28.5-­‐
43.5)	  
(72.3-­‐
164.3)	  
(14-­‐18)	   (3.9-­‐4.9)	   (411-­‐728.5)	   (1.7-­‐3.1)	  
(2.0-­‐
11.0)	  
	  
Prior	  
treatment	  
for	  
depression	  
Prior	  
treatment	  for	  
bipolar	  
disorder	  
No	  history	  
of	  alcohol	  
abuse	  
No	  history	  of	  
drug	  use	  
(ever)	  
No	  recent	  
drug	  use	  
(within	  1	  
month)	   	  
	  
Median/	  
Absolute	  
Total	  
20	   3	   32	   14	   26	  
	   	  
	  
Percentage	  
of	  Total	  
	  
(31.7%)	   (4.8%)	   (50.8%)	   (22.2%)	   (43.3%)	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Baseline Analysis of BDI and POMS Scores  
According to BDI definitions (total score >13), 31 (48%) of the 65 subjects met the 
criteria for clinical depression at baseline. Of those subjects, 11 had ‘mild’ depression, 11 
had ‘moderate’, and 9 had ‘severe’ depression (See Figure 6). A comparison of somatic 
performance proportional scores to cognitive-affective performance proportional scores, 
showed somatic scores were worse than cognitive-affective scores (medians 0.29 vs 0.15, 
p=.0045) (See Figure 7).  
 
	  
Figure 6: Depression During PHI by BDI Definition. Baseline depression severity in 
PHI subjects based on total BDI scores. 47.7 % met BDI criteria (total score > 13) for 
clinical depression.  
 
 
 
 
  
 
 
 
27 
 
Figure 7: Baseline BDI Subscale Scores. BDI subscale scores presented as a proportion 
of total possible points per scale.  Subjects reported greater somatic than affective 
symptoms.  Bold lines denote median value.   
 
Per the POMS measurement, the median Total Mood Disturbance was 44 (range -
21 to 167, with standard deviation of 41.64). Figure 8 shows the comparison between the 
different POMS subscales according to Z score. Vigor was the only state reduced in PHI 
subjects as compared to norms. The levels of tension, depression, confusion, anger and 
fatigue were similar.  Additionally, the BDI total score and POMS Total Mood 
Disturbance score correlated with one another (r = .85, p<.0001) (see Figure 9). This 
suggests internal reliability between the measures in our subjects, despite self-report. 
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Figure 8: Baseline Mood States: POMS Subscale Scores. POMS subscale scores at 
baseline. Only vigor was different (reduced) in PHI subjects compared with norms (Z 
scores).  Bars indicate median and interquartile range. 
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Figure 9: Correlation Between POMS Total Mood Disturbance and BDI Total 
Scores.  Strong and significant correlation suggests internal consistency of these 
measures in our subject cohort.  
 
We sought to investigate the possible effect of variables that may be associated 
with depression independent of HIV infection status on the mood states in our subjects.  
Scores on the BDI did not differ between groups defined based on the subject’s history of 
past drug use (p = 0.845), recent drug use (p = 0.885), alcohol abuse (p = 0.592), or prior 
psychiatric history/treatment, including depression or bipolar disorder (p = 0.875). 
 
Correlation of BDI and POMS Scores with Laboratory and Neuropsychological 
Performance Indicators 
 
No association was found between scores on BDI or POMS measurements and laboratory 
measures of HIV infection or CSF markers (not shown in table) associated with blood 
brain barrier breakdown (CSF: serum albumin ratio), macrophage activation (neopterin) 
or chemoattraction of inflammatory cells into the CNS (IP-10 and MCP-1) (Table 2). 
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Similarly, scores on mood measures did not correlate with either brief or total 
summarized NP measures, except an association between self-reported ‘vigor’ and better 
performance. The vigor Z score (median=-0.6) was reduced and modestly  
correlated with total z (r=0.33, p=0.013) and GDS (r= -0.32, p=0.016).  
 
 
Table 2.  Correlation Between Baseline BDI and POMS Scores and Laboratory 
Parameters and Neuropsychological (NP) Performance. Spearman r correlation value 
and p values are shown.  Significant correlations are shown in bold.  No significant 
correlations were identified between POMS Tension, Anger, Confusion or Fatigue 
subscores and lab or NP performance results.   
 
Longitudinal Analysis of BDI and POMS Scores  
 
Utilizing the same population of 65 subjects, we performed a longitudinal mixed-methods 
analysis on POMS and BDI scores. Only 60 of the 65 subjects from the baseline analysis 
could be used because 5 subjects did not have longitudinal follow-up. Understanding that 
a higher score is consistent with more depression on both the POMS and BDI measures, 
we did not detect a statistically significant improvement in the overall BDI either prior to 
 
CD4 count 
(cells/mm3) 
Plasma HIV 
RNA  
(log10copies/ml)  
CSF HIV RNA  
(log10copies/ml) 
CSF 
WBC 
NPZ-
4 
Total 
Z 
Score 
Global 
Deficit 
Score 
r= -0.11 r= 0.03 r= -0.091 r= 0.053 
r= -
0.13 
r= -
0.16 
r= 
0.14 BDI Total 
Score 
p= 0.35 p= 0.80 p= 0.53 p= 0.69 
p= 
0.37 
p= 
0.24 
p= 
0.32 
r= -0.13 r= -0.007 r= -0.032 r= 0.077 
r= -
0.055 
r= -
0.17 
r= 
0.18 POMS Total Mood 
Disturbance p= 0.32 p= 0.96 p= 0.83 p= 0.57 
p= 
0.69 
p= 
0.22 
p= 
0.20 
r= 0.55 r= -0.20 r= -0.071 r= -0.13 
r= 
0.18 
r= 
0.33 
r= -
0.32 POMS Vigor 
Subscore p=  0.66 p= 0.10 p= 0.59 p= 0.32 
p= 
0.18 
p= 
0.013 
p= 
0.016 
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or following HAART initiation (slope of change prior to treatment over time -0.02038 
change per week, p=0.1238; slope of change following ART= -0.0020, p=0.9107). The 
aggregate overall BDI trajectory (including pre- and post- HAART visits) also did not 
significantly change over the course of follow-up (slope= -.02239, p=0.0748).  On the 
POMS, there was a small significant improvement in depression prior to initiation of 
HAART (slope= -0.1229, p=0.0321), but neither the slope following HAART initiation 
(slope=0.1005, p=0.2308) nor the aggregate trajectory of POMS over total follow-up was 
significant (slope=-0.2246, p=0.7136). This data is represented by the spaghetti plots in 
Figures 10 (BDI) and 11 (POMS).  On top of the lines, which connect each subject’s 
trajectory, we have superimposed a Loess curve for each dataset to summarize the 
smooth average values of the data at each interval for visualization purposes. However, 
the statistical model that we used is more sophisticated than the Loess and factors in the 
variable duration and intervals of follow up for each subject, as well as their pre- versus 
post- HAART initiation status. 
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Figure 10. Longitudinal Total BDI Scores. Longitudinal BDI Total scores in those 60, 
of the initial 65 subjects with longitudinal follow-up, both before and after HAART 
initiation. Individual subject’s scores are represented here as symbols connected by lines 
to demonstrate the BDI score trajectory. A Lowess curve is superimposed on the lines to 
show the average scores at each time point and to provide an overview of the trajectory, 
but the more complex mixed model weights number of visits per subject and duration of 
follow-up. In this study, subjects had a total of 330 total visits, 196 of these off of ART. 
There were no changes in the BDI scores over a median 54 weeks of follow-up in 
longitudinal mixed model analyses either prior to or following HAART initiation (slope 
of change prior to treatment over time -0.02038 change per week, p=0.1238; slope of 
change following ART= -0.0020, p=0.9107). The aggregate overall BDI trajectory 
(including pre- and post- HAART visits) also did not significantly change over the course 
of follow-up (slope= -.02239, p=0.0748).  
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Figure 11.  Longitudinal POMS Total Mood Disturbance Scores. Longitudinal POMS 
Total Mood Disturbance scores in those 60, of the initial 65 subjects with longitudinal 
follow-up, both before and after HAART initiation. Individual subject’s scores are 
represented here as symbols connected by lines to demonstrate the BDI score trajectory. 
A Lowess curve is superimposed on the lines to show the average scores at each time 
point and to provide an overview of the trajectory, but the more complex mixed model 
weights number of visits per subject and duration of follow-up.  
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In this study, subjects had a total of 330 total visits, 196 of these off of ART. 
Except for a modest improvement in POMS prior to starting HAART (slope= -0.1229, 
p=0.0321), there was no significant change in POMS scores over a median 54 weeks of 
follow-up in longitudinal mixed model analyses; neither the slope following HAART 
initiation (slope=0.1005, p=0.2308) nor the aggregate trajectory of POMS over total 
follow-up was significant (slope=-0.2246, p=0.7136).  
Finally, to assess potential effects of timing of HAART initiation in the outcome 
of mood in early HIV infection, we examined whether post-ART POMS and BDI scores 
correlated with number of weeks from initial infection that HAART was started. In 
neither all subjects who started ART, nor the 18 subjects with at least 6 months sustained 
treatment with ART, were any significant associations detected between timing of the 
start of therapy (expressed as weeks from infection, a continuous factor) and subsequent 
BDI or POMS levels (data not shown).  
DISCUSSION 
 
We report on depression and mood states in 65 study participants who we followed 
longitudinally beginning in PHI. At baseline, we explored their depression and mood 
states as measured by the POMS and BDI and examined whether these correlated with 
neurological measures of inflammation and blood-brain barrier breakdown or 
performance on neuropsychological testing. Over a median 54 weeks follow-up, we also 
examined a model for depression and mood states pre- and post-initiation of ART.  
Depression is a Significant Problem in PHI 
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Studies have reported varying prevalence of depression over the course of HIV infection 
(37-39,41), though only one other study examined the population during PHI (68). Using 
the POMS and BDI, measures of mood that are considered valid and internally consistent 
(83,84) and have been used to measure depression with good validity and reliability in 
HIV infected patients (42,53,85), we determined that 47.7% of HIV-infected subjects at 
an estimated three and half months after HIV transmission experience clinical depression. 
While the overall prevalence of depression in our population was slightly higher (47.7 % 
as compared to 40 %), our findings resembled the results of the only other study, by 
Atkinson and colleagues (68), in that the vast majority of our PHI subjects experienced a 
minimal or mild depression (11 out of 65 subjects and 34 out of 65 subjects, 
respectively), as compared to a severe depression (9 out of 65). One subject in our study, 
however, did commit suicide, underscoring the potential severity of symptoms of 
depression that HIV-infected persons may experience. From this data, it is evident that 
depression is a significant and prevalent problem during PHI.  
As other chronic illnesses have been known to have 2-3 fold higher depression 
rates than the general population (35), our nearly 48% rate of depression during PHI 
supports the hypothesis that with HAART, HIV has features which parallel other chronic 
illnesses in the US population (7). Given that depressed patients who are chronically ill 
more frequently report physical symptoms and more pain (35,36), it is perhaps not 
surprising that in our study, as in other studies (42), HIV infected subjects experienced 
more somatic symptoms than cognitive/affective symptoms of depression. This was 
reflected in the increased BDI somatic-performance subscale as compared to the 
cognitive/affective subscale. These somatic symptoms could be associated with HIV 
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infection and its manifestations (38), and could be considered a confounding variable in 
the measurement of depression in this group. Additionally, the vigor subscale score was 
significantly lower than the other measured mood states, which may be expected in those 
experiencing a physical illness. However, given that as depression increases as physical 
symptoms of HIV infection increase (44), measuring depression in this population with 
reliable self-report tests might ideally be supplemented by psychological interviews. 
What Causes Depression in HIV Infection? 
 
Similar to the previous literature, our study is unable to definitively conclude what 
actually causes depression in HIV infected persons. One hypothesis suggests that 
depression is a premorbid condition in a person at high risk of HIV acquisition, or, in 
other words, a depressed person is inherently at a high risk to contract HIV (58). To 
support this theory, we would expect depression to be elevated in this population due to 
other confounding risk factors often associated with mood disorders, such as sexuality or 
substance use (58). However, as measured by either BDI or POMS in our study, 
depression was not associated with substance use, despite a high prevalence of alcohol 
and drug use in our cohort. In addition, though depression has been found to correlate 
with gender, social class, suicide attempts, and MSM in past studies (37, 38),  we had a 
homogenous group of 100% male subjects with all but 3 self-identifying as MSM, 
controlling for some of these variables.  
Another hypothesis postulates that depression in HIV is reactionary, and also 
associated with the manifestations and treatment of HIV itself. The high prevalence of 
clinical depression during PHI, a period characterized by dramatic systemic physiological 
effects, the emotional stress of recent disease diagnosis, and in some cases complex or 
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chaotic social settings, which led to infection, supports this theory. Additionally, as 
stigma in this population has been shown to correlate significantly with higher levels of 
depression (45,48,49), high levels of depression following diagnosis is not unexpected. 
However, given these social, emotional, and physical changes, one might expect the level 
of “severe” depression during this baseline period to be much higher than we detected 
(‘severe’ n=9). Also, both the opportunistic infections associated with HIV, and the side 
effects of antiretroviral therapy, are known to cause depression (38). In fact, one study 
found that increased side effects from treatment actually predicted depression (45). By 
selecting a population of treatment naive individuals, we protected against side effects 
causing any physical manifestations of depression. However, looking longitudinally after 
initiation of HAART, it becomes more difficult to assess whether symptoms such as 
insomnia that might manifest as high somatic performance scores and therefore higher 
scores on the total BDI, are a result of clinical depression or HAART.  
The final hypothesis for the development of depression during HIV suggests that 
there is a biological basis for disease. It is believed that cytokines, stress and cortisol, and 
the inhibition of dopamine, could all cause depression in the HIV infected person (38 34, 
48, 81). However, in our study, the lack of correlations between the BDI and POMS and 
any laboratory indices of disease (including blood or CSF HIV viral load or blood CD4 
count), suggests that depression should be considered independently from neuropathic 
HIV infection. This might also suggest that the high levels of depression in our 
population are reactive, and despite elevated somatic performance scores on the BDI, not 
caused by HIV infection’s influence on the physical and biological. Furthermore, our 
findings support the previous studies in chronic HIV indicating no association between 
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CD4 count, viral load, and depression, though there has been some conflicting evidence 
suggesting an association between these parameters and mood in HIV infected subjects at 
later stages of illness (38, 51). It is possible that unmeasured physiological effects 
contribute to mood disorders during the early stages of HIV infection, or, more likely, 
that the variable extent of HIV viral burden and host immune responses to early infection 
are independent of an individual’s self-reported mood.  
The lack of correlation between mood and neuropsychological testing further 
suggests that HIV is independent from depression, and conversely that impaired 
neurocognitive performance in this period is not directly caused by mood disturbance. 
While one might expect mood to influence cognitive performance as PHI alone is known 
to cause neuropsychological impairment (67), in our study, similar to the data found in 
additional studies that measured depression alone, or depression in those with HIV 
(86,87), neuropsychological performance (summarized as total Z and GDS) did not 
associate with BDI or POMS Total Mood Disturbance. The lack of correlation between 
performance and mood is important to interpretations of cognitive status during this early 
period of infection as poor performance in some subjects (67) might be attributed to 
disturbed mood during this challenging period. Our findings also suggests that the 
mechanisms of depression and other CNS pathology in HIV are different, as cognitive 
performance is impaired during PHI, but performance does not correlate with measures 
of depression during PHI.  Therefore, early depressive symptoms are unlikely to be a 
predictor for early HIV-associated neurocognitive disorder (HAND), and may also be 
unrelated to its’ later development. Though this study confirms that depression 
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prevalence is high in PHI, it remains uncertain whether depression is a predisposing 
factor to developing HIV or is, instead, an early result of the HIV infection itself.  
What Happens to Depression Over Time? 
 
Studies have suggested that depression can impact HIV disease progression and mortality 
(59). This is not shocking as depressed patients, even without a chronic illness, have been 
known to die 5 to 10 years earlier than patients without mood disorders (35). Yet, similar 
to effects of depression on treatment adherence in other chronic illnesses, non-adherence 
is high in patients with HIV and depression (60). Given that HAART has been postulated 
to have lowered the infection rates significantly (2) and to have increased life expectancy 
to close to the levels of the uninfected population with chronic disease (5), it is not 
surprising that HAART non-adherence is thought to contribute to the increased mortality 
found in depressed patients with HIV. One study even went so far as to postulate a 
protective effect of HAART, finding a decrease in depression with increased time on 
HAART (61).  
Our longitudinal data, however, does not support this theory. We found that the 
overall group’s BDI and POMS scores did not significantly change prior to or following 
initiation of HAART. This lack of statistically significant improvement in our results 
following treatment suggests that the course of HIV infection itself and its subsequent 
treatment with HAART might not play a role in alleviation of depression in PHI.  
Depression is also not changed whether the subject began HAART immediately after 
diagnosis, or later in the course of the disease.  
Overall, depression appears at a low level throughout the course of early HIV in 
our subjects suggesting that depression is persistent, regardless of causation, following 
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infection. Our results also suggest that “watchful waiting” did not improve depression 
scores except for a minor improvement in the POMS (slope=-.1229, p=0.0321) prior to 
ART, which was not sustained over the course of the pre- and post- HAART follow-up. 
One might expect time to improve depression, given the expectation that after adjustment 
to the news of HIV diagnosis there may be a natural improvement in mood over time 
without intervention. Since we did not see an improvement with the natural history of 
early HIV, it is possible that depression in this population also is less likely to be reactive, 
and more likely to be either a pre-morbid or HIV-related condition.  
Since depression is associated with lower adherence to HAART (62) and new 
treatment guidelines for HIV suggest commencing HAART at initial diagnosis (24), 
recognizing and treating depression in this population is important in management of 
HIV. Since it remains possible that depression in PHI is related to HIV infection itself, 
given the high somatic scores on the BDI, a synergistic approach to HAART and 
antidepressants might be an effective strategy in patients, especially those with early 
infection. Ultimately, the effects of treatment for depression, HAART adherence, HIV 
disease and symptom presentation in the early stages after HIV infection and diagnosis 
are in need of closer examination. 
Limitations  
 
The limitations of this study include a homogeneous population, primarily men who have 
sex with men (MSM) who live in the San Francisco area. In addition, depression is 
measured by self-report; however the scales correlate with each other suggesting internal 
consistency between our results. HAART adherence is also self-reported, though 
observation of persistent virological suppression this group (data not shown) suggests 
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excellent adherence over time in the subjects. The longitudinal correlations might be 
skewed by the effects of antidepressant usage, which are not included in our analysis, and 
the lack of randomization into ART. Also, we did not take an in depth psychological 
history at study visits, and merely relied on self-report of previous treatment for 
depression or bipolar disorder. This made it difficult to truly control for all of the 
psychological confounding variables that could affect depression rates in this population 
(e.g., previous suicidal attempts, antidepressant usage, previous treatment). 
Implications of Research for the HIV Field 
 
Our finding of 47.7% clinical depression in PHI has important implications for the 
management of patients with HIV. Since depression is associated with lower adherence 
to HAART (62) and new treatment guidelines for HIV suggest commencing HAART at 
initial diagnosis of HIV (24), our results would suggest that at diagnosis, it is also 
important to recognize and treat depression. Though the depression is more often mild or 
moderate, it can be severe, leading to suicide in these patients. Thus, beyond preventing 
non-adherence and resistance to HAART, treating depression might also save a life from 
self-harm.  
As depression does not seem to correlate with CSF measures of inflammation or 
disease or with neuropsychological testing, self-assessment and psychiatric consultation 
will be the most effective means of screening during PHI. In order to properly diagnose 
these patients, physicians must understand that the physical manifestations of disease 
may resemble depression (38), and must learn to screen by asking more about mood, 
anhedonia, and decreased energy than sleep and appetite changes (38). They must also 
recognize that depression may have been pre-morbid, and might seek to provide support, 
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suggest therapy or social services, or even drug rehabilitation, for their patients to help 
with the additional life factors that may be contributing to their depression. 
It also remains possible that depression in PHI is related to HIV infection itself, 
given the high somatic scores on the BDI.  The literature has suggested that 
antidepressants are effective in this population (38,41,58,62), and in fact, substantially 
increase adherence to HAART (63).  Therefore, a synergistic approach to HAART and 
antidepressants might be an effective strategy in patients, especially those with early 
infection. Also as our study suggests that depression remains consistent over time, despite 
initiation of ART, pharmacological treatment of depression may be the only way to 
significantly improve depression, with a significant impact of decreasing plasma viral 
load (65) in this population. Ultimately, the effects of treatment for depression, HAART 
adherence, HIV disease and symptom presentation in the early stages after HIV infection 
and diagnosis are in need of closer examination. 
Future Directions 
 
While we have characterized depression during PHI in our particular population, as it was 
only the second study of this early infection time period, it would be extremely useful to 
look at other populations for comparison. Given that this population was composed of 
only males, and studies have suggested higher rates of depression in females and 
increased mortality in females with HIV infection (43,55), doing a comparison study with 
women would be very important. Additionally, having a comparison group of matched 
individuals without HIV infection, or with another chronic illness, might help to better 
understand depression in this population as it relates to other chronic diseases and the 
“healthy” population.  
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Furthermore, though we were able to measure depression longitudinally in our 
population as an exploratory study, a more controlled environment would help to better 
describe the trajectory of depression. It would be necessary to document not only 
HAART initiation, but also treatment for depression, to see if antidepressant 
commencement or therapy initiation altered the prevalence of depression over time in any 
way. 
Finally, as we continue to study with whether depression was concomitant or was 
a result of the disease itself, we need to take a better assessment of stigma and support, 
psychological factors (like previous psychiatric treatment, suicide, or diagnoses), and 
substance use at baseline and over time. As depression is often a product of the social as 
well as the biological, these factors might contribute significantly to the high rates of 
depression we are seeing in this population.  
Conclusions 
 
While HIV may no longer be a death sentence upon diagnosis, depression may shorten an 
HIV-infected person’s life, whether by nonadherence to HAART or self-harm. This 
depression is highly prevalent, and though it is usually mild, it may be severe; in fact one 
of our 65 study subjects committed suicide during this early period. While it remains 
unclear whether depression is a predisposing factor to HIV infection or it is an early 
result of HIV infection itself, or whether it is merely persistent regardless of cause, this is 
an important area for future research and disease management protocols. Since HAART 
adherence is affected so significantly by depression, and failure to adhere leads to disease 
mutations and resistance to drugs as well as disease progression, screening for and 
properly treating depression in this population is critical. Targeted interventions for 
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depression in the early stages of infection may have an impact not only on psychological 
but also systemic outcomes in HIV. 
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